ClinicalTrials.gg
CompletedNCT07107841Updated Nov 19, 2026

Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

An interventional study of Autologous Hair Follicle-Derived Secretome and Placebo Control in Androgenic Alopecia, Alopecia and Baldness, sponsored by Acorn Biolabs Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Acorn Biolabs Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Enrollment
144th of 204
26 · median 40
Started
2025
with 19 others
No phase
93 of 217
24 open now
Registered
197th of 217
by date

Among the 217 studies in Alopecia with a site in United States, this one is the 144th largest by enrollment of the 204 interventional ones that give a count, is one of 20 that started in 2025, is one of 93 with no phase, and was the 197th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 127 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia. The secretome will be injected into the scalp at baseline, and days 30, 90, 180, 270 and 365.

Hair growth will be quantitatively measured for density and thickness. PROs will also be collected from participants. This study will be run at a SINGLE SITE.

Read the detailed description

(SINGLE SITE Study) Androgenic alopecia is a common condition causing hair loss and baldness in both men and women. Approximately 80 million men and women are affected by the condition in the US alone. Although there are a number of products on the market, both over the counter and prescribed, used for androgenic alopecia, they are only somewhat effective to slow the progression.

This trial will evaluate a new approach involving the injection of an autologous product made from the cellular secretions of hair follicles (secretome). Proteonomic analysis has demonstrated that this secretome contains anywhere from 2-22 times the bioactive components of platelet rich plasma (PRP) when compared within the same individual. The hypothesis is that repeat injections of autologous hair follicle-derived secretome will safely and effectively stimulate hair regrowth in men and women suffering from androgenic alopecia.

The trial is a double-blind, randomized, placebo controlled study in 60 patients who are on a stable (>6 months) regimen of minoxidil and 5 alfa-reductase inhibitors. The injections will be delivered at baseline (day 0), 30, 90, 180, 270 and 365 days as follows:

  • Each vial of secretome will be diluted with 2ml of saline
  • Each quadrant of the affected scalp will receive one vial of secretome
  • Injections will be delivered in a grid-like pattern with injections spaced \~1cm apart
  • Approximately 20 injections (0.1ml/injection) will be delivered to each alopecia affected quadrant
03

Conditions studied

  • Androgenic Alopecia
  • Alopecia
  • Baldness

Browse trials for

Keywords

  • secretome
  • alopecia
  • Hair
  • stem cells
  • androgenic
  • androgenetic
  • Hormone
  • scalp
  • hair loss
  • baldness
  • bald
  • hair follicle
  • Acorn
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SUBJECTS MUST BE ON A STABLE COURSE OF MINOXIDIL (ORAL OR TOPICAL) AND/OR 5-ALPHA REDUCTASE INHIBITORS. THEY MUST HAVE BEEN ON THE SAME 5-ALPHA REDUCTASE INHIBITOR FOR ≥12 MONTHS PRIOR TO BASELINE.
  • FEMALE SUBJECTS MUST NOT BE ON HAIR GROWTH MEDICATIONS OR TOPICALS FOR ≥6 MONTHS PRIOR TO BASELINE.
  • TESTOSTERONE REPLACEMENT THERAPY (TRT) IN ANY FORM (E.G. DEPO-, INJECTABLE, TOPICAL, PATCHES, NASAL GEL, ORAL, PELLET ETC.) IS ALLOWED AS LONG AS SUBJECT HAS BEEN ON A STABLE COURSE (IN THE OPINION OF THE INVESTIGATOR) OF TRT FOR ≥12 MONTHS.
  • Biological sex: Male and Female (up to n=20 males and up to n=10 females will be in each arm for a total of up to n=40 males and up to n=20 females)
  • Age: ≥18 - 65 years
  • Subjects with Androgenic alopecia
  • No intention to start new hair growth medications and no intention to change the dosage or usage of minoxidil or 5-alpha reductase inhibitors until the end of their participation in the trial.
  • Competent and willing to provide written, to participate in all study activities.
  • Willing and able to tolerate multiple injections of the study product.
  • Must be able to attend all study related clinical visits.
  • Willing to maintain the same hair style as at the Screening Visit for the duration of the study.
  • Must be willing to have small (diameter similar to a pencil lead) UV (invisible) or red colored tattoo dots applied to scalp (up to 5) and touch up tattoos if necessary. UV tattoo dots only show under black light. Subjects will chose UV or red.

Exclusion criteria

Exclusion Criteria

  • Subjects with clinical diagnosis of alopecia areata or other non-androgenic forms of alopecia.
  • Active skin disease (Psoriasis or severe seborrheic dermatitis) of the scalp
  • Scalp infection
  • Severe active systemic infection
  • Cuts or abrasions on the scalp
  • History of surgical hair restoration in the last 12 months.
  • Current or recent (within last 5 years) (except basal cell and squamous cell skin cancers)
  • History of systemic chemotherapy or radiation
  • History of thyroid dysfunction
  • History of disorder (specifically Graves disease, Hashimoto thyroiditis, or systemic lupus erythematosus)
  • Continuous/daily use of nonsteroidal anti-inflammatory or Vitamin E, unless discontinued within 7 days before 1st treatment and only used as needed through the trial period.
  • Use of any medications that potentially cause drug-induced hair loss (e.g., depo-testosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within the last 3 months.
  • Known allergy or sensitivity to tattoo ink.
  • Current anticoagulant therapy (heparins; factor Xa inhibitors; direct agents such dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban; warfarin/coumarins)
  • Significant tendency to develop keloids or hypertrophic scarring
  • Subjects unable to communicate with the investigator and staff
  • Any health condition that in the investigator's opinion should preclude participation in this study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    Active-Secretome

    Intervention is autologous hair follicle-derived secretome diluted in saline

    Other: Autologous Hair Follicle-Derived Secretome

  • Placebo comparator
    Placebo Control

    Placebo control is saline.

    Other: Placebo Control

Interventions

  • OtherAutologous Hair Follicle-Derived Secretome

    Hair follicles are plucked, cultured and the product is the resulting cell secretions (secretome) collected from the conditioned media.

    Also known as: aHFS

  • OtherPlacebo Control

    The same saline used for diluting the active treatment in will be used as a control.

06

What researchers measure

Primary outcomes

  1. Target Area Hair Counts (TAHC)

    Non-vellus TAHC is the number of non-vellus (terminal) hairs within 1 cm² scalp

    Time frame: 180 Days after Baseline

  2. Safety

    Incidence rates of treatment-related adverse events compared between the active and placebo arm

    Time frame: 180 days from Baseline

Secondary outcomes

  1. Mean Total Hair Density (vellus and non-vellus/terminal)

    Mean Total Hair Density (vellus and non-vellus/terminal): measured by Trichoscan device

    Time frame: 30, 90, 270 and 365 days

  2. Patient Satisfaction

    Patient satisfaction collected using a 5 point Likert scale

    Time frame: 30, 90, 270 and 365 days

  3. Hair thickness improvement

    Hair thickness improvement measured by Trichoscan device

    Time frame: 30, 90, 180, 270 and 365 days

  4. Patient Global Impression of Change (PGIC)

    Patient rated improvement in alopecia based on comparison of Baseline to follow-up time point

    Time frame: 180 and 365 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — This is a proof of concept study on a unique product unlike others so there is no reason to share IPD

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Nov 2026, 13 months.

Of 61 industry-sponsored interventional studies with no phase under Alopecia, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 13 months is above that.

Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Sep 2027 → Nov 2026 and completion Sep 2027 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 6, 2025
StartActual
Oct 16, 2025
Primary completionActual
Nov 17, 2026was Sep 2027
CompletionActual
Nov 17, 2026was Sep 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 19, 2026
Primary completion
Sep 15, 2027→Nov 17, 2026 (actual)
Nov 19, 2026
Study completion
Sep 15, 2027→Nov 17, 2026 (actual)
Nov 19, 2026
Enrollment
60 (estimated)→26 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Completed
    Primary completion Sep 15, 2027→Nov 17, 2026 (now actual)
    Study completion Sep 15, 2027→Nov 17, 2026 (now actual)
    Enrollment 60 (estimated)→26 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07107841
Lead sponsor
Acorn Biolabs Inc.
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Oct 16, 2025
Primary completion
Nov 17, 2026
Completion
Nov 17, 2026
Last update
Nov 19, 2026

Study contacts

Lisa M Campbell, PhD
study director · Acorn Biolabs

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion